Inovalon Holdings Inc

Inovalon — Q2 2017 Earnings Presentation

15 slides from Inovalon's earnings presentation, Aug 2, 2017

  1. Slide 1: Forward-looking statements

    2 This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including, but not limited to, statements regarding future results of the operations and financial position of Inovalon Holdings, Inc. (“Inovalon”), and i

  2. Slide 2: Contents

    3 This deck is provided as a supplement to the 2017 Q2 Earnings Results release announced by Inovalon on August 2, 2017. The following outlines the content of this supplemental presentation: Q2 2017 – Continued Sequential Improvement The Inovalon ONE™ Platform and Platform Storyboard MORE2 Registry®

  3. Slide 3: Q2 2017 – Continued Sequential Improvement

    16.3% 19.8% 10% 12% 14% 16% 18% 20% 22% Q1 2017 Q2 2017 Investment in Innovation 7.0% 8.0% 6% 7% 8% 9% Q1 2017 Q2 2017 Sales & Marketing 23.0% 25.1% 10% 15% 20% 25% 30% Q1 2017 Q2 2017 Adj. EBITDA Margin 64.7% 66.4% 50% 55% 60% 65% 70% Q1 2017 Q2 2017 Gross Margin Q2 2017 – Continued Sequential Impr

  4. Slide 4: The Inovalon ONE Platform

    5 The Inovalon ONE™ Platform brings to the marketplace highly extensible, national-scale capabilities to interconnect with the healthcare ecosystem on massive scale, aggregate and analyze data in petabyte volumes, arrive at sophisticated insights in real-time, and drive impact wherever it is analyti

  5. Slide 5: Inovalon ONE Platform Storyboard

    6 The Inovalon ONE™ Platform is an integrated, cloud-based platform of more than 80 individual proprietary toolsets able to be rapidly configured to empower the operationalization of large-scale, value-based care initiatives. Each toolset is referred to as a “Component,” with each supporting critica

  6. Slide 6: Expanded Proprietary Datasets

    Expanded Proprietary Datasets 7 *As of June 30, 2017, the Company was processing large unique patient count and medical event count dataset transmissions. For this reason, June 30, 2017 unique patient count and medical event count amounts vary from historical calculation methodologies, and represent

  7. Slide 7: 1H/2H 2017 Revenue Growth Trending

    8 The headwinds previously discussed by the Company have run their course as expected, resulting in a first-half 2017 revenue decline of 3% on a reported basis. In the second half of 2017, the Company continues to expect a return to double-digit growth, with growth expected to be approximately 17% a

  8. Slide 8: Seasonality Trends - Revenue

    Seasonality Trends - Revenue With the introduction of multiple new platform offerings and the expansion into several market adjacencies (e.g. provider, pharma, and devices), Inovalon continues to work towards a dampening of seasonality. Seasonality also reflects the impact of previously-discussed he

  9. Slide 9: Updated 2017 Revenue Guidance Bridge

    Updated 2017 Revenue Guidance Bridge The combination of previously-discussed factors in 2017 yields full year revenue guidance of $447.1M to $459.3M, or expected revenue growth between 5% and 7% on a reported basis. 10 Client revenue churn of approximately 6 pts in 2017 is consistent with historical

  10. Slide 10: Updated 2017 Adjusted EBITDA Margin Expansion

    Updated 2017 Adjusted EBITDA Margin Expansion Inovalon’s investments in innovation are driving increased platform efficiencies, while also enabling the introduction of new platform offerings with higher margins. These forces are enabling an expected 100 to 200 basis point expansion in annual Adjuste

  11. Slide 11: Updated 2017 Financial Guidance Summary

    Updated 2017 Financial Guidance Summary Inovalon is adjusting its full-year 2017 guidance to reflect strong year-to-date performance, updated visibility into second half 2017 expectations, and the acquisition of CCS (including non-recurring integration expenses). 12 INOV Q2 2017 Earnings Presentatio

  12. Slide 12: Updated 2017 Financial Guidance Summary

    Updated 2017 Financial Guidance Summary a Inovalon is adjusting its full-year 2017 guidance to reflect strong year-to-date performance, updated visibility into second half 2017 expectations, and the acquisition of CCS (including non-recurring integration expenses). Financial Metric Updated Guidance

  13. Slide 13: Adjusted EBITDA definition and forward-looking reconciliation

    14 Inovalon defines Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (Adjusted EBITDA) as net income calculated in accordance with GAAP, adjusted for the impact of depreciation and amortization, realized losses on short-term investments, gain on disposal of equipment, interest

  14. Slide 14: Reconciliation of Forward-Looking Guidance

    Reconciliation of Forward-Looking Guidance Non-GAAP Net Income Inovalon defines Non-GAAP net income as net income calculated in accordance with GAAP, adjusted to exclude tax-affected stock-based compensation expense, acquisition costs, amortization of acquired intangible assets, tax on equity exerci

  15. Slide 15: yu Woe

    yu Woe cS inovalon’

Inovalon Holdings — Q2 2017 Earnings Presentation on 6ix